Remus Pharmaceuticals Limited (NSE:REMUS)
India · Delayed Price · Currency is INR 804.00
-16.50 (-2.01%)
Nov 11, 2026, 1:24 PM IST
Remus Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 10,676 | 8,536 | 6,204 | 2,129 | 450.27 | 247.17 |
Other Revenue | 12.2 | 0.1 | - | - | 1.05 | - |
| 10,688 | 8,536 | 6,204 | 2,129 | 451.32 | 247.17 | |
Revenue Growth | 42.89% | 37.60% | 191.33% | 371.81% | 82.59% | 31.42% |
Cost of Revenue | 9,473 | 7,424 | 5,330 | 1,635 | 214.69 | 122.81 |
Gross Profit | 1,215 | 1,113 | 873.9 | 494.6 | 236.63 | 124.36 |
Selling, General & Admin | 146.2 | 128.2 | 131.1 | 73.2 | 54.7 | 34.24 |
Other Operating Expenses | 459.7 | 417.7 | 278.1 | 131.8 | 70.45 | 46.32 |
Operating Expenses | 636 | 573.5 | 427.9 | 216.2 | 129.92 | 82.1 |
Operating Income | 579.1 | 539.3 | 446 | 278.4 | 106.71 | 42.26 |
Interest Expense | -15.8 | -14.7 | -14.6 | -5 | -2.04 | -0.78 |
Interest & Investment Income | 25.5 | 25.5 | 29 | 22.5 | 3.48 | 2.45 |
Currency Exchange Gain (Loss) | 29.1 | 29.1 | 9.8 | 5.6 | 6.24 | 2.22 |
Other Non Operating Income (Expenses) | 4.7 | 4.8 | 1.1 | 0.1 | -0.26 | -0.09 |
EBT Excluding Unusual Items | 622.6 | 584 | 471.3 | 301.6 | 114.14 | 46.06 |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 0.08 |
Gain (Loss) on Sale of Assets | 0.2 | 0.2 | 2.1 | - | - | - |
Pretax Income | 630.2 | 591.6 | 473.4 | 301.6 | 114.14 | 46.13 |
Income Tax Expense | 137.9 | 129.9 | 89.2 | 58.9 | 29.11 | 11.79 |
Earnings From Continuing Operations | 492.3 | 461.7 | 384.2 | 242.7 | 85.03 | 34.34 |
Minority Interest in Earnings | -79.8 | -91.8 | -93.5 | -37.5 | - | - |
Net Income | 412.5 | 369.9 | 290.7 | 205.2 | 85.03 | 34.34 |
Net Income to Common | 412.5 | 369.9 | 290.7 | 205.2 | 85.03 | 34.34 |
Net Income Growth | 23.10% | 27.25% | 41.67% | 141.33% | 147.60% | 234.77% |
Shares Outstanding (Basic) | 12 | 12 | 6 | 11 | 8 | 8 |
Shares Outstanding (Diluted) | 12 | 12 | 6 | 11 | 8 | 8 |
Shares Change | -0.27% | 100.00% | -47.86% | 38.35% | 2.10% | - |
EPS (Basic) | 33.78 | 31.39 | 49.34 | 18.16 | 10.41 | 4.29 |
EPS (Diluted) | 33.78 | 31.39 | 49.34 | 18.16 | 10.41 | 4.29 |
EPS Growth | 23.43% | -36.38% | 171.71% | 74.43% | 142.51% | 234.77% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 24.1 | 35.9 | 30 | -19.4 | 25.81 | 49.67 |
Free Cash Flow Per Share | 1.97 | 3.05 | 5.09 | -1.72 | 3.16 | 6.21 |
Dividend Per Share | 0.500 | 1.000 | 1.500 | 0.750 | 0.250 | - |
Dividend Growth | -33.33% | -33.33% | 100.00% | 200.00% | - | - |
Gross Margin | 11.37% | 13.04% | 14.09% | 23.23% | 52.43% | 50.31% |
Operating Margin | 5.42% | 6.32% | 7.19% | 13.07% | 23.64% | 17.10% |
Profit Margin | 3.86% | 4.33% | 4.69% | 9.64% | 18.84% | 13.89% |
Free Cash Flow Margin | 0.22% | 0.42% | 0.48% | -0.91% | 5.72% | 20.09% |
EBITDA | 602.4 | 560.1 | 457.9 | 287.2 | 111.36 | 43.81 |
EBITDA Margin | 5.64% | 6.56% | 7.38% | 13.49% | 24.67% | 17.72% |
D&A For EBITDA | 23.3 | 20.8 | 11.9 | 8.8 | 4.64 | 1.55 |
EBIT | 579.1 | 539.3 | 446 | 278.4 | 106.71 | 42.26 |
EBIT Margin | 5.42% | 6.32% | 7.19% | 13.07% | 23.64% | 17.10% |
Effective Tax Rate | 21.88% | 21.96% | 18.84% | 19.53% | 25.50% | 25.56% |
Revenue as Reported | 10,755 | 8,603 | 6,253 | 2,158 | 466.05 | 254.37 |